Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Harbour BioMed Raises $221 Million in Hong Kong IPO

publication date: Dec 17, 2020

Harbour BioMed completed a $221 million Hong Kong IPO to continue its novel drug development. Headquartered in Cambridge, MA, HBM has a drug discovery CRO in Rotterdam and its own drug development operations in Suzhou. The company has built a portfolio of in-licensed late stage projects and internally developed early-stage assets in immunology and oncology. Yesterday, HBM announced it out-licensed rights for a SARS-CoV-2 neutralizing antibody to its partner AbbVie. In its first trading day, HBM's shares closed 11% lower. More details....

Stock Symbols: (HK: 02142) (NYSE: ABBV)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
The Ritz-Carlton Shanghai Pudong
March 23-25, 2021